TrialThe pharmacogenomics journal2004

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.

C Lerman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.